The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer

Authors:
  • TIthe Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators
    the Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators
  • NONick O’rOurke
    Nick O’rOurke

Abstract
While combination therapy with nab-paclitaxel/gemcitabine (nab-gem) is effective in pancreatic ductal adenocarcinoma (PDAC), its efficacy as perioperative
Funding Information
  • Specialised Therapeutics Australia
  • National Health and Medical Research Council of Australia (APP1026563)

This publication has 47 references indexed in Scilit: